B-Cell Lymphoma Videos

Andrew Zelenetz, MD, Memorial Sloan Kettering Cancer Center

Videos

R-CHOP Followed by R-ICE Regimen vs Standard-of-Care Therapy for Patients With Non-GCB DLBCL

03/12/2024

Featuring Andrew Zelenetz, MD

Andrew Zelenetz, MD, discusses next steps for evaluating long-term data on potential improved outcomes from R-CHOP induction preceding R-ICE consolidation vs standard-of-care therapy among patients with non-germinal center B-cell-like diffuse...

Andrew Zelenetz, MD, discusses...

03/12/2024

Oncology

Videos

Clinical Pathways in Practice at Roswell Park Cancer Center

09/05/2023

Stephen Edge , MD;

Stephen Edge, MD, vice president for system quality and outcomes at the Roswell Park Comprehensive Cancer Center and the University of Buffalo in Buffalo, New York, spoke with the Journal of Clinical Pathways about his experience using...

Stephen Edge, MD, vice president...

09/05/2023

Journal of Clinical Pathways

Videos

Overview of Treatment Options for Patients With Primary Refractory/Early Relapse Diffuse Large B-Cell Lymphoma

07/19/2023

Manali Kamdar , MD;

Manali Kamdar, MD, University of Colorado Cancer Center, discusses the latest therapeutic options available for patients with primary refractory/early relapse diffuse large B-cell lymphoma.

Manali Kamdar, MD, University of...

07/19/2023

Journal of Clinical Pathways

Videos

The Benefits of Incorporating Radiation Therapy Into the Treatment of Primary CNS Lymphoma

01/05/2023

At the 64th ASH Annual Meeting, Kathryn Tringale, MD, MAS, discusses outcomes with reduced-dose whole-brain radiation therapy as a consolidation regimen among patients with primary CNS lymphoma, suggesting the prospect of incorporating...

At the 64th ASH Annual Meeting,...

01/05/2023

Journal of Clinical Pathways

Videos

Retrospective Analysis of Survival Outcomes Following Treatment for Primary CNS Lymphoma

01/05/2023

Kathryn Tringale, MD, MAS, presented her study on patients with primary CNS lymphoma at the 64th Annual ASH Meeting, which analyzed survival outcomes after consolidation regimens and patterns of disease failure among over 500 patients treated...

Kathryn Tringale, MD, MAS,...

01/05/2023

Journal of Clinical Pathways

Videos

Developing a Prognostic Model for Patients With Follicular Lymphoma

12/14/2022

At the 64th Annual ASH Meeting, Matthew Maurer, DSc, discussed a prognostic model, the FLIPI24 model, that can identify a high-risk group of patients with FL who are likely to need novel therapies or should be considered for frontline...

At the 64th Annual ASH Meeting,...

12/14/2022

Journal of Clinical Pathways

Videos

The Value of Reducing CAR-T Treatment Wait Times Among Patients With Diffuse Large B-cell Lymphoma

10/04/2022

Alice J Chen, PhD, found that delays affected access to CAR-T treatments and treatment effectiveness among patients with refractory and relapsed aggressive blood cancer.

Alice J Chen, PhD, found that...

10/04/2022

Journal of Clinical Pathways

Videos

Patterns of Therapy Utilization in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

08/03/2022

Patrick Bliven, MD, discusses report patterns and therapy utilization in patients with relapsed/refractory diffuse large B-cell lymphoma, comparing overall survival among double-hit lymphoma (DHL) and non-DHL subgroups for chimeric antigen...

Patrick Bliven, MD, discusses...

08/03/2022

Journal of Clinical Pathways

Videos

Real-World Safety, Efficacy, and Utilization of Axicabtagene Ciloleucel and Tisagenlecleucel for B-Cell Lymphomas

01/21/2022

Peter Riedell, MD, discusses findings from a study that assessed safety, patterns of use, resource utilization, and efficacy with commercial axicabtagene ciloleucel and tisagenlecleucel for the treatment of relapsed/refractory B-cell...

Peter Riedell, MD, discusses...

01/21/2022

Journal of Clinical Pathways

Videos

Physician Survey Reveals Key Attributes for Third-Line Treatment Selection for DLBCL

10/18/2021

Patrick Connor Johnson, MD, discusses study results on physician perspectives regarding key attributes for selecting third-line treatment for DLBCL.

Patrick Connor Johnson, MD,...

10/18/2021

Journal of Clinical Pathways

Current Issue

October 2024

Volume 10

Issue 5

Current Issue

Issue Archive

Special Reports

Sponsored

JCP Special Report

The Value of Tissue-Based Genomic Profiling in Oncology

09/17/2024

Innovations in precision oncology have helped healthcare providers to create more personalized treatment plans and improve patient outcomes. View this special report to learn more.

Innovations in precision...

09/17/2024

Journal of Clinical Pathways

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee ;

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Robin T. Zon , MD, FACP, FASCO;

Gordon Kuntz ;

Winston Wong , PharmD;

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan ;

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Sponsored

Special Report

Navigating the Patient Journey for Unresectable Stage III Non-Small Cell Lung Cancer

09/16/2021

.ryan-test { display: none; } .body-content h3 { font-size: 18px; line-height: 18px; color: #000000; font-weight: 600px; } .related-content { display: none; } .body-content div > div:nth-of-type(3) .paragraph > h3 >...

.ryan-test { display:...

09/16/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

B-Cell Lymphoma Videos

Current Issue

Special Reports

Subscribe

Specialties

Events

Year Round Education

HMP Global Products